Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for prostate cancer: current recommendations.

Shandra S Wilson1, E David Crawford

  • 1Department of Urologic Oncology, Anschutz Cancer Center, 1665 North Ursula, Aurora, CO 80010, USA. shandra.wilson@uchsc.edu

The Urologic Clinics of North America
|May 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Robust Meta-Analysis of a Clinical Cell-Cycle Risk (CCR) Score Demonstrates Broadly Applicable Metastasis and Disease-Specific Mortality Risk Stratification in Men With Localized Prostate Cancer.

Clinical genitourinary cancer·2026
Same author

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.

JCO oncology practice·2024
Same author

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

Cancer·2024
Same author

Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.

Cancer medicine·2024
Same author

Editorial Comment on "Should Military Veterans Be Classified as High Risk for Prostate Cancer Screening? A Systematic Review and Meta-analysis".

Urology·2024
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Prostate cancer screening using prostate-specific antigen (PSA) has limitations but may still reduce disease progression and mortality. Ongoing research aims to improve PSA test accuracy for better early detection and patient outcomes.

Area of Science:

  • Urology
  • Oncology
  • Medical Diagnostics

Background:

  • Prostate-specific antigen (PSA) screening for prostate cancer faces scrutiny regarding its efficacy.
  • New techniques are under investigation to enhance the sensitivity and specificity of PSA testing.
  • The goal is to differentiate between lethal and non-lethal prostate cancers to mitigate lead-time bias.

Purpose of the Study:

  • To evaluate the continued role of PSA screening in prostate cancer detection.
  • To discuss ongoing research for improving PSA test accuracy.
  • To support the use of PSA screening despite its current limitations.

Main Methods:

  • Review of recent studies questioning PSA efficacy.
  • Investigation of new techniques for improved screening sensitivity and specificity.

Related Experiment Videos

  • Analysis of data from Scandinavian studies and advanced disease mortality.
  • Consideration of prospective, randomized, long-term screening trials (e.g., PLCO, ERSCP).

    • Main Results:

    • Current PSA screening, despite limitations, contributes to stage migration.
    • Evidence suggests a decrease in disease progression after surgical treatment in some studies.
    • Patients with advanced prostate cancer exhibit significant mortality.

    Conclusions:

    • PSA screening remains a valuable tool for prostate cancer detection, potentially reducing disease progression.
    • Improved screening methods are crucial for differentiating cancer types and avoiding unnecessary treatments.
    • Long-term studies are expected to further clarify the survival benefits of PSA screening.